Neoantigen vaccines are a type of personalized cancer vaccine. While clinical trials have shown promising results, it is important to note that neoantigen vaccines are still in the early stages of development. Further research is needed to develop successful anti-cancer vaccines. For example, one of the challenges is identifying vaccine delivery systems that allow vaccines to be produced quickly and cost-effectively.

In this webinar, we will review neoantigen vaccines and their current status. We will discuss the different vaccine formats, especially peptide and mRNA, and GenScript's solutions for advancing the development of neoantigen vaccines.

Learning Objectives: 

1. Summarize the Neoantigen vaccine introduction and status. 

2. Review the importance of neoantigen peptide for all forms of neoantigen vaccines. 

3. Outline key considerations for mRNA vaccine outsourcing.